API
< Back to all clusters
[HEALTH] · Malaysia · 2 sources

started · updated

Malaysia Ministry of Health approves 240 diabetes and obesity drug applications

The Malaysian Ministry of Health (KKM) approved 240 applications for treatments to manage type 2 diabetes and obesity between January and September. These approvals involved GLP-1 receptor agonist medications, such as Ozempic and Mounjaro, with a total cost of RM2.56 million.

Health Minister Datuk Seri Dr. Dzulkefly Ahmad stated in the Dewan Rakyat that these treatments were approved through the Special Drug Approval (UKK) mechanism based on individual clinical needs and health conditions. While no specific allocation was set aside for these drugs in the 2026 Budget, the ministry utilized existing KKM funds to cover the costs.

Dr. Dzulkefly noted that while oral medications like metformin are typically the first line of treatment for diabetes, GLP-1 drugs are considered for patients with specific clinical requirements, such as obesity or related complications. He emphasized that obesity is a chronic disease requiring continuous management, noting that approximately 7.63 million Malaysians aged 18 and older are estimated to be obese, increasing risks for cardiovascular disease, high blood pressure, and certain cancers.

Entities

Dewan Rakyat · Dzulkefly Ahmad · Ministry of Health Malaysia